期刊
IMMUNOTHERAPY
卷 13, 期 3, 页码 201-216出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0195
关键词
biologics; IL-17A; psoriasis; psoriatic arthritis; secukinumab
类别
Secukinumab, a monoclonal antibody targeting IL-17A, has shown significant efficacy in improving symptoms and PASI scores in clinical trials, with long-term data confirming its safety and effectiveness for the treatment of psoriasis.
Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17A and is approved by the US FDA and European Medicines Agency for moderate-to-severe plaque psoriasis and psoriatic arthritis. This review examines the efficacy and safety of secukinumab for the treatment of psoriasis using the literature retrieved from the PubMed database. In clinical trials, treatment with secukinumab led to rapid and sustained improvement in Psoriasis Area and Severity Index (PASI) scores, with PASI 90 response rates up to 68.5% at 5 years. Long-term clinical trial and real-world data have established secukinumab as a safe and effective treatment for psoriasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据